Previous Close | 2.9900 |
Open | 2.9400 |
Bid | 0.0000 x 3100 |
Ask | 0.0000 x 2900 |
Day's Range | 2.8700 - 3.0600 |
52 Week Range | 0.7200 - 4.4600 |
Volume | 489,475 |
Avg. Volume | 717,872 |
Market Cap | 343.192M |
Beta (5Y Monthly) | 1.64 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.5840 |
Earnings Date | Nov 10, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.60 |
If you want to know who really controls MEI Pharma, Inc. ( NASDAQ:MEIP ), then you'll have to look at the makeup of its...
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Phase 1b trial arm exploring zandelisib, an investigational selective phosphatidylinositol 3-kinase ("PI3K") delta inhibitor, in combination with zanubrutinib (marketed as BRUKINSA®), an inhibitor of Bruton's tyrosine kinase ("BTK") developed by BeiGene, Ltd. ("BeiGene"), completed the safety evaluation stage in patients with B-cell malignancies and is expanding into disease specific B-cell malignancy cohorts. The Safety Review Committee recommended moving forward with a dosing regimen found to be generally well tolerated and active following a planned safety analysis.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into MEI Pharma, Inc. (NasdaqGS: MEIP).